buy medicine online indiamedicine onlineloading...

    Ranibizumab

    Information about Ranibizumab

    Ranibizumab uses

    Ranibizumab is used for diabetic eye disease, wet age-related macular degeneration and macular oedema due to retinal vein occlusion.

    How ranibizumab works

    Ranibizumab is an anti-angiogenic medication. It works by blocking a protein called vascular endothelial growth factor (VEGF). This stops the growth and leakage of abnormal blood vessels in the eye(s) that may cause vision loss.

    Common side effects of ranibizumab

    Conjunctival hemorrhage, Eye pain, Eye inflammation, Eye floaters, Increased intraocular pressure
    Content Details
    author-image
    Written By
    Dr. Radhika Dua
    MDS, BDS
    author-image
    Reviewed By
    Dr. Shilpa Garcha
    MD (Pharmacology), MBBS
    Last updated on:
    14 Aug 2018 | 12:35 PM (IST)
    editorial-image
    Want to know more?
    Read Our Editorial Policy

    Available Medicine for Ranibizumab

    • ₹17000
      Intas Pharmaceuticals Ltd
      1 variant(s)
    • ₹70160
      Novartis India Ltd
      1 variant(s)
    • ₹23960
      Novartis India Ltd
      1 variant(s)

    Expert advice for Ranibizumab

    • Ranibizumab is used for the treatment of eye diseases caused by diabetes, macular degeneration and macular swelling.
    • It is administered directly into the eyeball by an eye specialist.
    • It may cause temporary visual disturbances. Don't drive or do anything that requires mental focus until you know how Ranibizumab affects you.
    • Inform your doctor if you experience increased eye pain and redness, blurred or decreased vision, or increased sensitivity to light.

    Frequently asked questions for Ranibizumab

    Ranibizumab

    Q. Is Ranibizumab FDA approved?

    Yes, Ranibizumab is approved by the FDA

    Q. What is Ranibizumab injection and how does it work?

    Ranibizumab injection belongs to a class of medications called vascular endothelial growth factor (VEGF) antagonists. Ranibizumab is used for the treatment of conditions that affect vision such as exudative (wet) neovascular age-related macular degeneration (AMD), macular edema (swelling) following retinal vein occlusion and macular edema (swelling) due to diabetes. Ranibizumab binds extracellular VEGF thereby stopping abnormal blood vessel growth and leakage in the eye(s) which may lead to vision loss in people with wet AMD.

    Content on this page was last updated on 14 August, 2018, by Dr. Varun Gupta (MD Pharmacology)